Bupa’s latest half-year results aren’t just good – they’re the kind of numbers that make you sit up and take notice. When a healthcare giant serving over 40 million insurance customers globally posts a 32% surge in underlying profit, we’re looking at more than just a strong quarter. This is a business firing on all cylinders.
The Headline Grabbers
Let’s cut straight to the chase:
- Profit surge: Underlying profit before tax hit £560m – up 32% at constant exchange rates (CER). Even on a statutory basis, profits jumped 14% to £582m.
- Customer growth: Insurance customers soared by 23% to 40.9 million. That’s not just a number – it’s 7.6 million more people choosing Bupa in six months.
- Revenue momentum: £8.8bn in revenue represents 11% organic growth. Healthcare isn’t supposed to grow this fast.
- Operational excellence: Aged care occupancy hit 94% (up 1 percentage point), while provision customers served increased 7% to 15.1 million.
What’s Fueling This Engine?
CEO Iñaki Ereño’s “3×100 Strategy” isn’t corporate fluff – it’s driving tangible results. The ambition? A Net Promoter Score of 100, 100% complete customer datasets, and supporting 100 million customers. But strategies only matter when executed, and Bupa’s delivering:
Geographic Powerhouses
- Asia Pacific (32% of profit): 7% revenue growth to £3.1bn. Australia’s health insurance arm grew market share for the tenth consecutive quarter, while Hong Kong’s pricing strategy paid dividends.
- Europe & Latin America (36% of profit): The star performer with 14% revenue growth and 44% profit surge. Poland’s LUX MED and Chile’s recovery were standouts, while Spain’s Sanitas Seguros entered Portugal.
- Global/India/UK (22% of profit): 12% revenue growth powered by Niva Bupa’s turnaround to profitability and UK health services expansion. India now represents over 22 million customers alone.
Digital & Physical Expansion
Bupa’s playing a dual game: scaling digital while expanding physical touchpoints:
- Blua’s rocket ship: Their digital health solution now serves 8.1 million customers – averaging 94,000 video consultations monthly in Spain alone.
- Bricks-and-mortar growth: 61 new health sites opened globally, including hospitals in Madrid and Poland. The UK’s acquiring New Victoria Hospital – their first hospital purchase there since 2008.
- Mindplace initiative: Seven mental health centres launched toward a three-year target of 200 worldwide.
Financial Fortress
Beyond the growth, the balance sheet sings:
- Solvency II ratio: Strengthened to 182% (from 176%) – comfortably above their 140-170% target range.
- Cash generation: £977m from operations – up 30% year-on-year. That’s the kind of liquidity that funds ambitious expansion.
- Leverage: Reduced to 16.4% (excluding lease liabilities). Prudent, especially with October’s Fitch upgrade to ‘A’ stable.
The Human Element
Often overlooked but critical:
- Customer love: 91% of business units improved Net Promoter Scores year-on-year, with 57% scoring over 70.
- Colleague engagement: An 83 score in their global survey – putting them in the top 10% globally. Happy teams drive happy customers.
- Genomics frontier: Over 9,000 participants in DNA analysis pilots across Spain, UK and Poland – pioneering personalised care pathways.
Why This Matters for Investors
This isn’t just a COVID rebound story. Bupa’s demonstrating structural growth in a sector with immense tailwinds – ageing populations, rising health awareness, and digital adoption. The 3×100 Strategy provides clear metrics to track ambition against execution. Trading at 182% solvency with reduced leverage creates headroom for strategic acquisitions (like the upcoming New Victoria Hospital) while maintaining investor security.
The risks? Geopolitical uncertainty and regulatory changes remain watchpoints. But with diversified global operations and this level of operational momentum, Bupa’s looking like a healthcare play that’s finally delivering on its potential. When a not-for-profit reinvesting its profits achieves growth like this, you know the model’s working. Health may be their business, but these results are positively sickening for competitors.
